Circulating Immune Landscape Profiling in Psoriasis Vulgaris and Psoriatic Arthritis by Mass Cytometry

Xudong Sang,Tian Gan,Gai Ge,Dan Li,Youming Mei,Chun Pan,Siyu Long,Bibo Xie,Xiaobing Yu,Zhiming Chen,Hongsheng Wang

DOI: https://doi.org/10.1155/2024/9927964

IF: 4.4929

2024-04-02

Journal of Immunology Research

Abstract:Background. Psoriasis, a systemic disorder mediated by the immune system, can appear on the skin, joints, or both. Individuals with cutaneous psoriasis (PsC) have an elevated risk of developing psoriatic arthritis (PsA) during their lifetime. Despite this known association, the cellular and molecular mechanisms underlying this progression remain unclear. Methods. We performed high-dimensional, in-depth immunophenotyping of peripheral blood mononuclear cells (PBMCs) in patients with PsA and psoriasis vulgaris (PsV) by mass cytometry. Blood samples were collected before and after therapy for a longitudinal study. Then three sets of comparisons were made here: active PsA vs. active PsV, untreated PsV vs. treated PsV, and untreated PsA vs. treated PsA. Results. Marked differences were observed in multiple lymphocyte subsets of PsA related to PsV, with expansion of CD4+ T cells, CD16− NK cells, and B cells. Notably, two critical markers, CD28 and CD127, specifically differentiated PsA from PsV. The expression levels of CD28 and CD127 on both Naïve T cells (TN) and central memory CD4+ T cells (TCM) were considerably higher in PsA than PsV. Meanwhile, after treatment, patients with PsV had higher levels of CD28hi CD127hi CD4+ TCM cells, CD28hi CD127hi CD4+ TN cells, and CD16− NK cells. Conclusion. In the circulation of PsA patients, the TN and CD4+ TCM are characterized with more abundant CD28 and CD127, which effectively distinguished PsA from PsV. This may indicate that individuals undergoing PsV could be stratified at high risk of developing PsA based on the circulating levels of CD28 and CD127 on specific cell subsets.

immunology

What problem does this paper attempt to address?

The problems that this paper attempts to solve are: **To clarify the immunological mechanisms of the progression from psoriasis (PsV) to psoriatic arthritis (PsA), and to find biomarkers that can distinguish these two diseases and predict the development of PsA in PsV patients**.

### Specific problem analysis:
1. **Background problems**:
- Psoriasis (PsV) is a chronic inflammatory disease mediated by the immune system. Approximately 75% - 80% of psoriatic arthritis (PsA) patients have had skin lesions before the appearance of joint symptoms.
- Currently, PsA lacks specific biomarkers, resulting in diagnosis relying on clinical evaluation and imaging examinations, and the treatment effect is not as significant as that of PsV.
- Therefore, researchers hope to find the immunological characteristics of the progression from PsV to PsA in order to identify high - risk populations and conduct early interventions.

2. **Scientific problems**:
- **Differences at the cellular and molecular levels**: Are there significant differences in immune cell subsets and molecular expressions between PsV and PsA?
- **Potential biomarkers**: Which immune markers can effectively distinguish PsV and PsA?
- **Predictive indicators**: Can the risk of PsV patients developing into PsA be predicted by the expression levels of specific immune markers?

3. **Research objectives**:
- Use mass cytometry (CyTOF) to analyze peripheral blood mononuclear cells (PBMCs) and compare the circulating immune landscapes of PsV and PsA patients.
- Determine the significant differences in immune cell subsets and molecular expressions between PsV and PsA.
- Explore the changes in the immune landscape of PsV patients before and after treatment and look for possible compensation mechanisms or risk signals.

### Problems mainly solved in the paper:
Through in - depth analysis of the circulating immune cell subsets and molecular expressions of PsV and PsA patients, the study found that:
- The expressions of **CD28 and CD127** in PsA patients are significantly higher than those in PsV patients, especially in naive T cells (T_N) and central memory CD4⁺T cells (T_CM).
- After treatment, the CD28^hiCD127^hiCD4⁺T_CM and CD28^hiCD127^hiCD4⁺T_N subsets in PsV patients increase significantly, suggesting that there may be compensation mechanisms or arthritis risk signals.
- These findings indicate that monitoring the expression levels of CD28 and CD127 in specific cell subsets may help to identify individuals with a high risk of developing PsA among PsV patients.

### Summary:
The core problem of this paper is **to reveal the immunological mechanisms of the progression from PsV to PsA and to explore the prediction model based on circulating immune markers**. The research results provide a new direction for the early diagnosis and preventive treatment of PsA.